Scott Struthers - Crinetics Pharmaceuticals CEO, Co-Founder, Director
| CRNX Stock | USD 56.09 0.03 0.05% |
CEO
Dr. R. Scott Struthers is President, Chief Executive Officer, Director of the Company. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the companys efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he cofounded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery since 2008.
| Age | 61 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Address | 6055 Lusk Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 450 6464 |
| Web | https://www.crinetics.com |
Crinetics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2429) % which means that it has lost $0.2429 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4026) %, meaning that it created substantial loss on money invested by shareholders. Crinetics Pharmaceuticals' management efficiency ratios could be used to measure how well Crinetics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.35 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Crinetics Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 382 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Found 4 records | CEO Age | ||
| Joseph MBA | Milestone Pharmaceuticals | 56 | |
| Eric MBA | Seres Therapeutics | 48 | |
| John Tucker | Scpharmaceuticals | 61 | |
| BAO BCh | Eliem Therapeutics | 48 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 |
Crinetics Pharmaceuticals Leadership Team
Elected by the shareholders, the Crinetics Pharmaceuticals' board of directors comprises two types of representatives: Crinetics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crinetics. The board's role is to monitor Crinetics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Crinetics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crinetics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Knight, Chief Officer | ||
| James Hassard, Chief Officer | ||
| Adriana MBA, Chief Officer | ||
| Gayathri Diwakar, Head Relations | ||
| Stephen Betz, Co-Founder, Vice President - Biology | ||
| Dana MD, Chief Officer | ||
| Marc Wilson, Chief Officer | ||
| Kevin Capps, Head Property | ||
| Scott Struthers, CEO, Co-Founder, Director | ||
| Alan MD, Chief Endocrinologist | ||
| Garlan Adams, General Secretary | ||
| Chris MBA, Chief Officer | ||
| Marc CPA, Chief Officer |
Crinetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crinetics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (295.25) % | ||||
| Current Valuation | 4.39 B | ||||
| Shares Outstanding | 92.74 M | ||||
| Shares Owned By Insiders | 1.79 % | ||||
| Shares Owned By Institutions | 94.68 % | ||||
| Number Of Shares Shorted | 6.94 M | ||||
| Price To Earning | (12.03) X | ||||
| Price To Book | 6.24 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.